基于分子对接与代谢组学的表没食子儿茶素没食子酸酯抗白念珠菌生物膜机制

Mechanism of epigallocatechin gallate against Candida albicans biofilm based on molecular docking and metabolomics

  • 摘要: 目的 从待选药物库中筛选出具有抗黏附的凝集素样序列蛋白3(ALS3)潜在配体;明确表没食子儿茶素没食子酸酯(EGCG)抗菌、抗生物膜活性,初步探讨其代谢组学机制。方法 以ALS3为靶蛋白,采用分子对接虚拟筛选的方法筛选出对生物膜形成有潜在抵抗作用ALS3抑制剂;通过微量液基稀释法测定EGCG对白念珠菌的最低抑菌浓度(MIC)和最小杀菌浓度(MBC),绘制时间生长曲线;采用二甲氧唑黄(XTT)法探索EGCG对白念珠菌生物膜形成及成熟生物膜弥散作用;结合代谢组学测序筛选差异代谢物,初步探究EGCG抗生物膜机制。结果 通过Glide三级筛选得到69个化合物,获得打分优秀且模式结合可观的化合物EGCG。EGCG MIC 256 μg/ml,MBC 1 024 μg/ml,呈时间剂量依赖性。EGCG对白念珠菌生物膜50%抑制率浓度为256 μg/ml,当浓度达到1 024 μg/ml时可抑制80%生物膜形成,分散40%的生物膜;非靶向代谢组学结果表明,EGCG作用下的白念珠菌与对照组比较,差异代谢物总数505个(86个上调,419个下调),主要富集代谢通路:辅因子生物合成,ABC转运蛋白,氨基酸生物合成,碳水化合物代谢等。结论 以ALS3为靶点,使用虚拟筛选方法寻找抗白念珠菌生物膜苗头化合物具有可行性;EGCG对白念珠菌具有一定的抗菌及抗生物膜活性,且有分散生物膜作用;EGCG通过干扰了多个代谢通路,从根基上瓦解其能量供应、结构基础和生物合成能力,同时削弱其防御并暴露其脆弱性。

     

    Abstract: OBJECTIVE To screen potential ligands with anti-adhesion agglutinin-like sequence protein 3 (ALS3) from a candidate drug library; clarify the antibacterial and anti-biofilm activities of epigallocatechin gallate (EGCG) and preliminarily explore its metabolomic mechanism. METHODS Using ALS3 as the target protein, molecular docking virtual screening was employed to identify ALS3 inhibitors with potential resistance to biofilm formation. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of EGCG against Candida albicans were determined using the microbroth dilution method, and the time-growth curve was plotted. The XTT assay was used to explore the effects of EGCG on the formation and dispersion of mature biofilms of C. albicans. Differential metabolites were screened by combining metabolomic sequencing to preliminarily investigate the anti-biofilm mechanism of EGCG. RESULTS A total of 69 compounds were obtained through Glide tertiary screening, and EGCG, which scored excellently and demonstrated considerable binding mode, was identified. The MIC of EGCG was 256 μg/ml, and the MBC was 1,024 μg/ml, showing time-dose dependence. The concentration of EGCG that inhibited 50% of C. albicans biofilm formation was 256 μg/ml, and when the concentration reached 1,024 μg/ml, it could inhibit 80% of biofilm formation and disperse 40% of the biofilm. Non-targeted metabolomic results indicated that, compared with the control group, C. albicans treated with EGCG had a total of 505 differential metabolites (86 upregulated and 419 downregulated), primarily enriched in metabolic pathways such as cofactor biosynthesis, ABC transporters, amino acid biosynthesis, and carbohydrate metabolism. CONCLUSIONS It is feasible to use virtual screening methods to identify lead compounds against C. albicans biofilm with ALS3 as the target; EGCG exhibits certain antibacterial and anti-biofilm activities against C. albicans and has a dispersing effect on biofilms; EGCG disrupts multiple metabolic pathways, fundamentally undermining its energy supply, structural basis, and biosynthetic capacity, while weakening its defense and exposing its vulnerability.

     

/

返回文章
返回